283 related articles for article (PubMed ID: 17021816)
61. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
62. Imaging of apoptosis (programmed cell death) with 99mTc annexin V.
Blankenberg FG; Katsikis PD; Tait JF; Davis RE; Naumovski L; Ohtsuki K; Kopiwoda S; Abrams MJ; Strauss HW
J Nucl Med; 1999 Jan; 40(1):184-91. PubMed ID: 9935075
[TBL] [Abstract][Full Text] [Related]
63. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
64. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
65. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.
McQuade P; Martin KE; Castle TC; Went MJ; Blower PJ; Welch MJ; Lewis JS
Nucl Med Biol; 2005 Feb; 32(2):147-56. PubMed ID: 15721760
[TBL] [Abstract][Full Text] [Related]
66. Imaging of therapy-induced apoptosis using (99m)Tc-HYNIC-annexin V in thymoma tumor-bearing mice.
Wong E; Kumar V; Howman-Giles RB; Vanderheyden JL
Cancer Biother Radiopharm; 2008 Dec; 23(6):715-26. PubMed ID: 19111046
[TBL] [Abstract][Full Text] [Related]
67. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
68. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model.
Kuge Y; Sato M; Zhao S; Takei T; Nakada K; Seki KI; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2004 Feb; 45(2):309-12. PubMed ID: 14960654
[TBL] [Abstract][Full Text] [Related]
69. Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody.
Kobayashi H; Sakahara H; Endo K; Hosono M; Yao ZS; Toyama S; Konishi J
Jpn J Cancer Res; 1995 Mar; 86(3):310-4. PubMed ID: 7744702
[TBL] [Abstract][Full Text] [Related]
70. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression.
Kang CM; Koo HJ; Lee KC; Choe YS; Choi JY; Lee KH; Kim BT
Biomaterials; 2013 Sep; 34(28):6839-45. PubMed ID: 23787114
[TBL] [Abstract][Full Text] [Related]
71. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.
Belhocine T; Steinmetz N; Hustinx R; Bartsch P; Jerusalem G; Seidel L; Rigo P; Green A
Clin Cancer Res; 2002 Sep; 8(9):2766-74. PubMed ID: 12231515
[TBL] [Abstract][Full Text] [Related]
72. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
73. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
74. Development of antibody-carrying microbubbles based on clinically available ultrasound contrast agent for targeted molecular imaging: a preliminary chemical study.
Otani K; Yamahara K
Mol Imaging Biol; 2011 Apr; 13(2):250-6. PubMed ID: 20512420
[TBL] [Abstract][Full Text] [Related]
75. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
76. Cu
Han J; Wang X; Yu M
Bioorg Med Chem Lett; 2016 Nov; 26(22):5594-5596. PubMed ID: 27780640
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
78. PET of vascular endothelial growth factor receptor expression.
Cai W; Chen K; Mohamedali KA; Cao Q; Gambhir SS; Rosenblum MG; Chen X
J Nucl Med; 2006 Dec; 47(12):2048-56. PubMed ID: 17138749
[TBL] [Abstract][Full Text] [Related]
79. Tumor targeting by an aptamer.
Hicke BJ; Stephens AW; Gould T; Chang YF; Lynott CK; Heil J; Borkowski S; Hilger CS; Cook G; Warren S; Schmidt PG
J Nucl Med; 2006 Apr; 47(4):668-78. PubMed ID: 16595502
[TBL] [Abstract][Full Text] [Related]
80. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin.
Saga T; Weinstein JN; Jeong JM; Heya T; Lee JT; Le N; Paik CH; Sung C; Neumann RD
Cancer Res; 1994 Apr; 54(8):2160-5. PubMed ID: 8174123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
